ab-16b5
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02412462)
Timeline
Indications
Mechanism of action
- ClusterinINHIBITOR
CLU inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068591 ↗
Also known as
- ab-16b5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06225843 | Phase 2 | Feb 15, 2024 | Alethia Biotherapeutics |
| NCT04364620 | Phase 2 | Aug 31, 2020 | Alethia Biotherapeutics |
| NCT02412462 | Phase 1 | Apr 1, 2015 | Alethia Biotherapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alethia Biotherapeutics | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1